感染症治療薬市場：薬剤、投与経路、疾患、流通チャネル、エンドユーザー別-2025-2030年の世界予測

感染症治療薬市場は、2023年に1,162億1,000万米ドルと評価され、2024年には1,212億7,000万米ドルに達すると予測され、CAGR 4.41％で成長し、2030年には1,572億8,000万米ドルに達すると予測されています。

感染症治療薬は、ウイルス、細菌、真菌、寄生虫などの病原体によって引き起こされる感染症と闘うために開発された治療法や医薬品を指します。抗ウイルス剤、抗菌剤、抗真菌剤、抗寄生虫剤に加え、ワクチンや個別化医療も含まれます。この治療薬セグメントの必要性は、絶え間ない感染症の発生、新興感染症、薬剤耐性株の増加によって強調されており、公衆衛生を守るために革新的な治療が必要とされています。用途は病院、診療所、在宅医療など多岐にわたり、エンドユーザーには医療従事者や患者が含まれます。同市場の主な成長要因としては、感染症の罹患率の上昇、多額の研究開発投資、高度なヘルスケア・インフラを推進する政府の取り組みなどが挙げられます。さらに、COVID-19のパンデミックは、迅速なワクチン開発と先進的な治療ソリューションの必要性を浮き彫りにし、活発な資金調達と研究機運を生み出しています。注目すべきビジネスチャンスは、抗生物質耐性感染症をターゲットにした革新的な薬剤の開発、広域抗ウイルス薬、オーダーメイド治療を促進するゲノム医療の進歩にあります。アジア太平洋とアフリカの新興市場開拓は、ヘルスケア・アクセスの改善と感染症患者の増加により、大きな成長の可能性を秘めています。このような見通しにもかかわらず、この分野は、研究開発コストの高さ、複雑な規制状況、病原体の突然変異の予測不可能性といった課題に直面しており、薬剤の有効性を複雑にしています。これらを克服するためには、官民の強固な協力体制と承認プロセスの迅速化が推奨されます。事業拡大に不可欠なイノベーション分野には、遺伝子治療、mRNAワクチン技術、AIを活用した創薬手法などがあり、画期的な成果が期待できます。同市場は、技術的優位性と市場シェアを目指して鎬を削る世界的・地域的プレイヤーの多さによる激しい競合が特徴であり、継続的なイノベーションと戦略的提携が必要となります。研究を実用的な治療薬に迅速に転換することは、進化する感染症の状況に効果的に対応するために不可欠です。

市場力学：急速に進化する感染症治療薬市場の主要市場インサイトを公開

感染症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の感染症の流行拡大
  • 感染症の負担を軽減するための政府の取り組みと迅速な行動
  • 特許切れとジェネリック医薬品参入の増加
• 市場抑制要因
  • 感染症治療薬による健康への悪影響
• 市場機会
  • 感染症治療のための新薬開発への投資の急増
  • 感染症に対する免疫療法の最近の進歩
• 市場の課題
  • 感染症管理のための代替治療法の利用可能性

ポーターの5つの力：感染症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：感染症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、感染症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析感染症治療薬市場における競合情勢の把握

感染症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス感染症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、感染症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨感染症治療薬市場における成功への道筋を描く

感染症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で感染症の蔓延が増加
    • 感染症の負担を軽減するための政府の取り組みと迅速な行動
    • 特許切れとジェネリック医薬品の導入増加
  • 抑制要因
    • 感染症治療薬による健康被害
  • 機会
    • 感染症治療の新薬開発への投資急増
    • 感染症に対する免疫療法の最近の進歩
  • 課題
    • 感染症管理のための代替治療法の利用可能性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 感染症治療薬市場薬物別

• 抗生物質
• 抗真菌薬
• 抗寄生虫薬
• 抗ウイルス薬

第7章 感染症治療薬市場：投与経路別

• 静脈内
• オーラル
• 話題

第8章 感染症治療薬市場：疾患別

• 肝炎
• HIV
• インフルエンザ
• マラリア
• 結核

第9章 感染症治療薬市場：流通チャネル別

• オフライン
• オンライン

第10章 感染症治療薬市場：エンドユーザー別

• 在宅ケア施設
• 病院・クリニック

第11章 南北アメリカの感染症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の感染症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの感染症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Alexion Pharmaceuticals, Inc.
• Allergan PLC
• Amgen Inc.
• Astellas Pharma US, Inc.
• AstraZeneca PLC
• Bayer AG
• BioCryst Pharmaceuticals, Inc.
• Biogen Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• Chimerix, Inc.
• Eli Lilly and Company
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Mitsubishi Chemical Group Corporation
• Mylan N.V.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

• FIGURE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INFECTIOUS DISEASE THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPARASITIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MALARIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 45. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 72. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 74. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 77. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 79. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 163. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 165. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 166. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 183. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 185. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 188. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 190. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 191. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 238. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Infectious Disease Therapeutics Market was valued at USD 116.21 billion in 2023, expected to reach USD 121.27 billion in 2024, and is projected to grow at a CAGR of 4.41%, to USD 157.28 billion by 2030.

Infectious Disease Therapeutics refers to treatments and drugs developed to combat infectious diseases caused by pathogens such as viruses, bacteria, fungi, and parasites. The scope of this market is broad, enveloping antiviral, antibacterial, antifungal, and antiparasitic agents, alongside vaccines and personalized medicine. The necessity of this therapeutics segment is underscored by continual outbreaks, emerging infectious diseases, and an increasing prevalence of drug-resistant strains, which require innovative treatments to safeguard public health. Applications extend across hospitals, clinics, and home healthcare settings, with end-users including healthcare providers and patients. Key growth influencers in the market include the rising incidence of infectious diseases, substantial R&D investments, and government initiatives promoting advanced healthcare infrastructure. Furthermore, the COVID-19 pandemic has highlighted the critical need for rapid vaccine development and advanced therapeutic solutions, creating invigorated funding and research momentum. Noteworthy opportunities lie in the development of innovative drugs targeting antibiotic-resistant infections, broad-spectrum antivirals, and advancements in genomic medicine facilitating tailored treatments. Developing markets in Asia-Pacific and Africa present considerable growth potential due to improving healthcare access and rising infectious disease cases. Despite these prospects, the sector faces challenges such as high R&D costs, complex regulatory landscapes, and the unpredictability of pathogen mutation, complicating drug efficacy. To overcome these, robust public-private collaborations and accelerated approval processes are recommended. Innovation areas crucial for business expansion include gene therapy, mRNA vaccine technologies, and AI-driven drug discovery methods, which hold promise for breakthrough results. The market is characterized by intense competition due to a plethora of global and regional players striving for technological superiority and market share, necessitating continuous innovation and strategic alliances. Emphasizing the swift translation of research into actionable therapeutics remains imperative to meet the evolving landscape of infectious diseases effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Disease Therapeutics Market

The Infectious Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of infectious disease across the globe
  • Government initiatives and prompt actions to reduce the burden of infectious disease
  • Increasing number of patent expirations and entry of generic drugs
• Market Restraints
  • Adverse health outcomes of infectious disease drugs
• Market Opportunities
  • Surging investments for development of new drugs to treat infectious diseases
  • Recent advances in immunotherapies against infectious disease
• Market Challenges
  • Availability of alternative treatments for infectious disease management

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Disease Therapeutics Market

A detailed market share analysis in the Infectious Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Infectious Disease Therapeutics Market

A strategic analysis of the Infectious Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Infectious Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals, Inc., Allergan PLC, Amgen Inc., Astellas Pharma US, Inc., AstraZeneca PLC, Bayer AG, BioCryst Pharmaceuticals, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Chimerix, Inc., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Chemical Group Corporation, Mylan N.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Infectious Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across Antibiotics, Antifungal Drugs, Antiparasitic Drugs, and Antiviral Drugs.
• Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
• Based on Disease, market is studied across Hepatitis, HIV, Influenza, Malaria, and Tuberculosis.
• Based on Distribution Channel, market is studied across Offline and Online.
• Based on End-User, market is studied across Homecare Facilities and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of infectious disease across the globe
    • 5.1.1.2. Government initiatives and prompt actions to reduce the burden of infectious disease
    • 5.1.1.3. Increasing number of patent expirations and entry of generic drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse health outcomes of infectious disease drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Surging investments for development of new drugs to treat infectious diseases
    • 5.1.3.2. Recent advances in immunotherapies against infectious disease
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of alternative treatments for infectious disease management
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Infectious Disease Therapeutics Market, by Drug

• 6.1. Introduction
• 6.2. Antibiotics
• 6.3. Antifungal Drugs
• 6.4. Antiparasitic Drugs
• 6.5. Antiviral Drugs

7. Infectious Disease Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intravenous
• 7.3. Oral
• 7.4. Topical

8. Infectious Disease Therapeutics Market, by Disease

• 8.1. Introduction
• 8.2. Hepatitis
• 8.3. HIV
• 8.4. Influenza
• 8.5. Malaria
• 8.6. Tuberculosis

9. Infectious Disease Therapeutics Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Offline
• 9.3. Online

10. Infectious Disease Therapeutics Market, by End-User

• 10.1. Introduction
• 10.2. Homecare Facilities
• 10.3. Hospitals & Clinics

11. Americas Infectious Disease Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Infectious Disease Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Infectious Disease Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alexion Pharmaceuticals, Inc.
• 3. Allergan PLC
• 4. Amgen Inc.
• 5. Astellas Pharma US, Inc.
• 6. AstraZeneca PLC
• 7. Bayer AG
• 8. BioCryst Pharmaceuticals, Inc.
• 9. Biogen Inc.
• 10. Boehringer Ingelheim GmbH
• 11. Bristol-Myers Squibb Company
• 12. Celgene Corporation
• 13. Chimerix, Inc.
• 14. Eli Lilly and Company
• 15. Gilead Sciences, Inc.
• 16. GlaxoSmithKline PLC
• 17. Johnson & Johnson Services, Inc.
• 18. Merck & Co., Inc.
• 19. Mitsubishi Chemical Group Corporation
• 20. Mylan N.V.
• 21. Novartis AG
• 22. Novo Nordisk A/S
• 23. Pfizer Inc.
• 24. Sanofi S.A.
• 25. Takeda Pharmaceutical Co. Ltd.